These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27601016)

  • 21. Type 2 diabetes and the polycystic ovary syndrome.
    Pelusi B; Gambineri A; Pasquali R
    Minerva Ginecol; 2004 Feb; 56(1):41-51. PubMed ID: 14973409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polycystic ovary syndrome, obesity and reproductive implications.
    Hirschberg AL
    Womens Health (Lond); 2009 Sep; 5(5):529-40; quiz 541-2. PubMed ID: 19702452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fracture Risk Is Decreased in Women With Polycystic Ovary Syndrome: A Register-Based and Population-Based Cohort Study.
    Rubin KH; Glintborg D; Nybo M; Andersen M; Abrahamsen B
    J Bone Miner Res; 2016 Apr; 31(4):709-17. PubMed ID: 26542642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of obesity and polycystic ovary syndrome in adolescents.
    Vilmann LS; Thisted E; Baker JL; Holm JC
    Horm Res Paediatr; 2012; 78(5-6):269-78. PubMed ID: 23208318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term complications of polycystic ovary syndrome (PCOS).
    Peigné M; Dewailly D
    Ann Endocrinol (Paris); 2014 Sep; 75(4):194-9. PubMed ID: 25156132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity and the polycystic ovary syndrome.
    Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
    Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgens and polycystic ovary syndrome.
    Nisenblat V; Norman RJ
    Curr Opin Endocrinol Diabetes Obes; 2009 Jun; 16(3):224-31. PubMed ID: 19390322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obese but not normal-weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance.
    Ketel IJ; Stehouwer CD; Serné EH; Korsen TJ; Hompes PG; Smulders YM; de Jongh RT; Homburg R; Lambalk CB
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3365-72. PubMed ID: 18593766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
    Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
    Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polycystic ovarian syndrome.
    Madnani N; Khan K; Chauhan P; Parmar G
    Indian J Dermatol Venereol Leprol; 2013; 79(3):310-21. PubMed ID: 23619436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age.
    Pasquali R; Gambineri A
    Ann N Y Acad Sci; 2006 Dec; 1092():158-74. PubMed ID: 17308142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
    Otto-Buczkowska E; Jarosz-Chobot P; Deja G
    Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Best methods for identification and treatment of PCOS.
    Artini PG; Di Berardino OM; Simi G; Papini F; Ruggiero M; Monteleone P; Cela V
    Minerva Ginecol; 2010 Feb; 62(1):33-48. PubMed ID: 20186113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp.
    Stepto NK; Cassar S; Joham AE; Hutchison SK; Harrison CL; Goldstein RF; Teede HJ
    Hum Reprod; 2013 Mar; 28(3):777-84. PubMed ID: 23315061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance.
    Vgontzas AN; Legro RS; Bixler EO; Grayev A; Kales A; Chrousos GP
    J Clin Endocrinol Metab; 2001 Feb; 86(2):517-20. PubMed ID: 11158002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.
    Cussons AJ; Stuckey BG; Watts GF
    Atherosclerosis; 2006 Apr; 185(2):227-39. PubMed ID: 16313910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity and the polycystic ovary syndrome.
    Gambineri A; Pelusi C; Vicennati V; Pagotto U; Pasquali R
    Int J Obes Relat Metab Disord; 2002 Jul; 26(7):883-96. PubMed ID: 12080440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.